|
ZFP90 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.75570000549419E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.35879999996202E-06 |
| Normal-vs-Stage2 |
2.841300E-03 |
| Normal-vs-Stage3 |
5.40689999994903E-07 |
| Normal-vs-Stage4 |
2.78109999996001E-06 |
| Stage1-vs-Stage2 |
6.776200E-01 |
| Stage1-vs-Stage3 |
1.397370E-01 |
| Stage1-vs-Stage4 |
1.787830E-01 |
| Stage2-vs-Stage3 |
1.878430E-01 |
| Stage2-vs-Stage4 |
1.662220E-01 |
| Stage3-vs-Stage4 |
8.625800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.08149999955565E-07 |
| Normal-vs-AfricanAmerican |
9.642500E-03 |
| Normal-vs-Asian |
2.764800E-03 |
| Caucasian-vs-AfricanAmerican |
7.011200E-01 |
| Caucasian-vs-Asian |
2.429000E-01 |
| AfricanAmerican-vs-Asian |
6.678200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.47339999995366E-06 |
| Normal-vs-Female |
1.39880000027404E-07 |
| Male-vs-Female |
6.302200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.54052999999932E-05 |
| Normal-vs-Age(41-60Yrs) |
2.38460000001606E-06 |
| Normal-vs-Age(61-80Yrs) |
6.78389999952955E-07 |
| Normal-vs-Age(81-100Yrs) |
1.548490E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.480600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.892190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.208600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.527400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.292800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.641800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.622500E-03 |
| Classical-VS-Follicular |
2.279500E-03 |
| Classical-VS-Other |
3.177600E-01 |
| Classical-VS-Normal |
5.240000E-04 |
| Tall-VS-Follicular |
6.182600E-01 |
| Tall-VS-Other |
7.435600E-01 |
| Tall-VS-Normal |
2.17250000000835E-06 |
| Follicular-VS-Other |
9.703000E-01 |
| Follicular-VS-Normal |
4.94789999971879E-07 |
| Other-VS-Normal |
3.426200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.10509999995401E-06 |
| Normal-vs-N1 |
7.88240000049178E-07 |
| N0-vs-N1 |
2.070800E-01 |
|
|
